Cyclacel Pharmaceuticals, Inc. Announces Closing of Underwritten Offering of Common Stock and Warrants
BERKELEY HEIGHTS, N.J. , July 7, 2011 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that it has closed its previously announced underwritten offering of an aggregate of 7,617,646 units at an offering price of $1.36 per unit for gross proceeds of $10.36 million . Each unit consists of (i) one share of common stock and (ii)a five-year warrant to purchase 0.5 of a share of common stock at an exercise price of $1.36 per share, exercisable beginning six months after the date of issuance. The shares of common stock and warrants are immediately separable and were issued separately such that no units were issued. […]
Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.
Cyclacel’s ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia.
Three product candidates are in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, will be entering Phase 3 development for the treatment of Acute Myeloid Leukemia in the elderly under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration, and is in Phase 2 studies for myelodysplastic syndromes and lung cancer. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.
CorMedix Submits Design Dossier for Neutrolin (CRMD003) to Start European Approval Process
BRIDGEWATER, N.J. –(BUSINESS WIRE)– CorMedix Inc. (CorMedix) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced today that it submitted its design dossier to a prominent European notified body as part of the CE Marking approval process for Neutrolin in the prevention of Catheter Related Bloodstream Infections (CRBI) and maintenance of catheter patency in hemodialysis catheters. […]
CorMedix, Inc., a development-stage biopharmaceutical company, develops, manufactures, and markets products that lock a patient’s central venous catheter between hemodialysis sessions to keep it free of infection and clots. It provides CMX001 that reduces oxidative stress due to excess labile iron; CMX002, a diagnostic test for chronic kidney disease; CMX003, an antimicrobial/anticoagulant solution; and CMX004, a pressure-sensitive gel.
ECOtality Closes $3.2 Million Over-Allotment Option
SAN FRANCISCO –(BUSINESS WIRE)– ECOtality, Inc. (NASDAQ:ECTY) has closed the sale of an additional 1,275,000 shares of common stock at the public offering price of $2.50 per share for gross proceeds to the company of $3.2 million , pursuant to the 30-day over-allotment option exercised in full by the underwriters in connection with ECOtality’s underwritten public offering that closed on June 27, 2011 .
The full exercise of the over-allotment option brings the total number of shares sold by ECOtality in the public offering to 9,775,000 shares. The company expects to receive an aggregate of approximately $22.7 million in net proceeds from the public offering after deducting underwriting discounts, commissions, legal fees, and offering expenses payable by the company. […]
ECOtality, INC., through its subsidiaries, provides clean electric transportation and storage technologies in the United States and internationally. It offers electric vehicle supply equipment for on-road vehicular applications under the Blink name; and advanced fast-charge systems for material handling, airport ground support equipment, and various motive applications under the Minit-Charger name, as well as engages in the development, manufacture, assembly, and sale of specialty solar products, advanced battery systems, and hydrogen and fuel cell systems.
American Diversified Holdings Corporation’s Operating Subsidiary Rebel Networks to Penetrate $160 Billion Cloud Computing Industry by Expanding Affiliate Program to Include Cloud Hosting and Cloud Computing
DEL MAR Calif. , July 7, 2011 (GLOBE NEWSWIRE) — REBEL NETWORKS, a wholly owned operating subsidiary of American Diversified Holdings Corporation (Pink Sheets:ADHC), announced today that it is offering an AFFILIATE MARKETING PROGRAM, allowing its customers and partners an opportunity to generate revenue by placing banner ads on their Rebel Networks hosted websites.
American Diversified Holdings Corporation is developing a platform for the Mobile Health Care Market as the medical profession gears up to go electronic not only for medical records but also for direct patient monitoring and information. ADHC’s mHealth Division will Focus on Mobile Health Care Applications for iPhone™, iPad™, Android™ and Other Mobile Devices. ADHC is developing applications for the iPhone, iPad, Android and Other Mobile Devices tailored for specific ailments and protocols to allow medical professionals to monitor patients, get instant feedback and constantly adjust treatments to allow greater flexibility and response time in meeting individual patient needs.